Glucocorticoid and pyrazolone treatment of acute fever is a risk factor for critical and life-threatening human enterovirus 71 infection during an outbreak in China, 2008

Pediatric Infectious Disease Journal

Volumn 29, Issue 6, 2010, Pages 524-529

  Ma, Huilai ^a   He, Fan ^a   Wan, Junfeng ^b   Jin, Donghui ^a   Zhu, Liye ^b   Liu, Xuxiang ^a   Liu, Qiquan ^b   Zhang, Guohong ^a   Ding, Zhentao ^b   Fontaine, Robert E ^c   Zhu, Bao Ping ^a   Jian, Haihui ^b   Zhang, Lijie ^a   Xu, Wenbo ^a   Zeng, Guang ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b Fuyang Center for Disease Control and Prevention   (China)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Antipyretics; Fever treatment; Glucocorticoids; Human enterovirus 71 infection; Pyrazolones; Severity of disease

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID; METHYLPREDNISOLONE; PYRAZOLONE DERIVATIVE;

AGE; ANTHROPOMETRY; ARTICLE; BREATHING RATE; CASE CONTROL STUDY; CHILD; CHILD DEATH; CHILD NUTRITION; CHILDHOOD MORTALITY; CHINA; CONTROLLED STUDY; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; EPIDEMIC; FATALITY; FEMALE; FEVER; HEART RATE; HUMAN; INFANT; INFECTION RISK; LEUKOCYTE COUNT; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; PATIENT MOBILITY; PRESCHOOL CHILD; PRIORITY JOURNAL; REFLEX; RISK FACTOR; SEX DIFFERENCE; SKIN COLOR; TEMPERATURE; ACUTE DISEASE; CHEMICALLY INDUCED; ENTEROVIRUS; ISOLATION AND PURIFICATION; NONPARAMETRIC TEST; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX; VIROLOGY;

ACUTE DISEASE; CHILD; CHILD, PRESCHOOL; CHINA; DISEASE OUTBREAKS; ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; FEMALE; FEVER; GLUCOCORTICOIDS; HUMANS; INFANT; MALE; PYRAZOLONES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 77953159366     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181cdd178     Document Type: Article

References (49)

1. Alexander JP Jr, Baden L, Pallansch MA, et al. Enterovirus 71 infections and neurologic disease - United States, 1977-1991. J Infect Dis. 1994;169: 905-908.
2. Witso E, Palacios G, Ronningen KS, et al. Asymptomatic circulation of HEV71 in Norway. Virus Res. 2007;123:19-29.
3. Kehle J, Roth B, Metzger C, et al. Molecular characterization of an Enterovirus 71 causing neurological disease in Germany. J Neurovirol. 2003;9:126-128.
4. Khetsuriani N, Lamonte-Fowlkes A, Oberst S, et al. Enterovirus surveillance - United States, 1970-2005. MMWR Surveill Summ. 2006;55:1-20.
5. Jee YM, Cheon DS, Kim K, et al. Genetic analysis of the VP1 region of human enterovirus 71 strains isolated in Korea during 2000. Arch Virol. 2003;148:1735-1746.
6. McMinn P, Stratov I, Nagarajan L, et al. Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in western Australia. Clin Infect Dis. 2001;32:236-242.
7. Merovitz L, Demers AM, Newby D, et al. Enterovirus 71 infections at a Canadian center. Pediatr Infect Dis J. 2000;19:755-757.
8. Ooi EE, Phoon MC, Ishak B, et al. Seroepidemiology of human enterovirus 71, Singapore. Emerg Infect Dis. 2002;8:995-997.
9. Prager P, Nolan M, Andrews IP, et al. Neurogenic pulmonary edema in enterovirus 71 encephalitis is not uniformly fatal but causes severe morbidity in survivors. Pediatr Crit Care Med. 2003;4:377-381.
10. Tagaya I, Takayama R, Hagiwara A. A large-scale epidemic of hand, foot and mouth disease associated with enterovirus 71 infection in Japan in 1978. Jpn J Med Sci Biol. 1981;34:191-196.
11. Shindarov LM, Chumakov MP, Voroshilova MK, et al. Epidemiological, clinical, and pathomorphological characteristics of epidemic poliomyelitislike disease caused by enterovirus 71. J Hyg Epidemiol Microbiol Immunol. 1979;23:284-295.
12. Nagy G, Takatsy S, Kukan E, et al. Virological diagnosis of enterovirus type 71 infections: experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. Arch Virol. 1982;71:217-227.
13. Shekhar K, Lye MS, Norlijah O, et al. Deaths in children during an outbreak of hand, foot and mouth disease in Peninsular Malaysia - clinical and pathological characteristics. Med J Malaysia. 2005;60:297-304.
14. Chan LG, Parashar UD, Lye MS, et al; for the Outbreak Study Group. Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: clinical and pathological characteristics of the disease. Clin Infect Dis. 2000;31:678-683.
15. Huang CC, Liu CC, Chang YC, et al. Neurologic complications in children with enterovirus 71 infection. N Engl J Med. 1999;341:936-942.
16. Ho M, Chen ER, Hsu KH, et al. Taiwan Enterovirus Epidemic Working Group. An epidemic of enterovirus 71 infection in Taiwan. N Engl J Med. 1999;341:929-935.
17. Shimizu H, Utama A, Onnimala N, et al. Molecular epidemiology of enterovirus 71 infection in the Western Pacific region. Pediatr Int. 2004; 46:231-235.
18. Bible JM, Pantelidis P, Chan PK, et al. Genetic evolution of enterovirus 71: epidemiological and pathological implications. Rev Med Virol. 2007;17: 371-379.
19. McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev. 2002;26:91-107.
20. Cardosa MJ, Krishnan S, Tio PH, et al. Isolation of subgenus B adenovirus during a fatal outbreak of enterovirus 71-associated hand, foot, and mouth disease in Sibu, Sarawak. Lancet. 1999;354:987-991.
21. Guidelines for the Clinical Diagnosis and Treatment of HFMD. Chinese Ministry of Health; 2008. Available at: http://www.gov.cn/gzdt/2008-12/ 12/content-1176057.htm. Accessed June 9, 2009.
22. Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated pediatric risk of mortality score. Crit Care Med. 1996;24:743-752.
23. McCarthy PL, Sharpe MR, Spiesel SZ, et al. Observation scales to identify serious illness in febrile children. Pediatrics. 1982;70:802-809.
24. Chang LY, Hsiung CA, Lu CY, et al. Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71. Pediatr Res. 2006;60:466-471.
25. Liu ML, Lee YP, Wang YF, et al. Type I interferons protect mice against enterovirus 71 infection. J Gen Virol. 2005;86:3263-3269.
26. Yang KD, Yang MY, Li CC, et al. Altered cellular but not humoral reactions in children with complicated enterovirus 71 infections in Taiwan. J Infect Dis. 2001;183:850-856.
27. Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs, inhibitors of the synthesis and actions of adrenocortical hormones. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill; 2006; chap 59.
28. McGowan JE Jr, Chesney PJ, Crossley KB, et al; Working Group on Steroid Use, Antimicrobial Agents Committee, Infectious Diseases Society of America. Guidelines for the use of systemic glucocorticosteroids in the management of selected infections. J Infect Dis. 1992;165:1-13.
29. Grom AA. Fever and the inflammatory response. In: Long S, ed. Principles and Practice of Pediatric Infectious Disease. 3rd ed. Philadelphia: Churchill Livingstone; 2008; chap 11.
30. Chen YC, Yu CK, Wang YF, et al. A murine oral enterovirus 71 infection model with central nervous system involvement. J Gen Virol. 2004;85:69-77.
31. Yuan J, Liu Y, Yang Z, et al. Mycobacterium abscessus post-injection abscesses from extrinsic contamination of multiple-dose bottles of normal saline in a rural clinic. Int J Infect Dis. 2009;13:537-542.
32. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11:954-963.
33. Costa D, Marques AP, Reis RL, et al. Inhibition of human neutrophil oxidative burst by pyrazolone derivatives. Free Radic Biol Med. 2006;40: 632-640.
34. Rezende RM, Franca DS, Menezes GB, et al. Different mechanisms underlie the analgesic actions of paracetamol and dipyrone in a rat model of inflammatory pain. Br J Pharmacol. 2008;153:760-768.
35. Witte KW, West DP. Immunology of adverse drug reactions. Pharmacotherapy. 1982;2:54-65.
36. Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med. 2007;146:657-665.
37. Meulenhoff JS. Adverse effects of drugs on the blood. Pharm Weekbl Sci. 1984;6:39-47.
38. Parker CW. Allergic reactions in man. Pharmacol Rev. 1982;34:85-104.
39. Diaz-Quijano FA, Villar-Centeno LA, Martinez-Vega RA. Effectiveness of early dipyrone administration on severity of dengue virus infection in a prospective cohort [in Spanish]. Enferm Infecc Microbiol Clin. 2005;23: 593-597.
40. Solomon T, Kneen R, Dung NM, et al. Poliomyelitis-like illness due to Japanese encephalitis virus. Lancet. 1998;351:1094-1097.
41. Liu HZ. Analysis on the epidemiological characteristics of epidemic encephalitis B in Hefei. J Dis Control. 2001;5:71-72.
42. Chen SC, Chang HL, Yan TR, et al. An eight-year study of epidemiologic features of enterovirus 71 infection in Taiwan. Am J Trop Med Hyg. 2007;77:188-191.
43. Schulman CI, Namias N, Doherty J, et al. The effect of antipyretic therapy upon outcomes in critically ill patients: a randomized, prospective study. Surg Infect (Larchmt). 2005;6:369-375.
44. Su F, Nguyen ND, Wang Z, et al. Fever control in septic shock: beneficial or harmful? Shock. 2005;23:516-520.
45. Blatteis C. Fever: pathological or physiological, injurious or beneficial? J Therm Biol. 2003;28:1-13.
46. Mackowiak PA. Concepts of fever. Arch Intern Med. 1998;158:1870-1881.
47. Rantala S, Vuopio-Varkila J, Vuento R, et al. Predictors of mortality in beta-hemolytic streptococcal bacteremia: a population-based study. J Infect. 2009;58:266-272.
48. Greisman L, Mackowiak P. Fever: beneficial and detrimental effects of antipyretics. Curr Opin Infect Dis. 2002;15:241.
49. Powell KR. Fever. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. Nelson Textbook of Pediatrics. 18th ed. Philadelphia: Saunders; 2007: 1084-1087.